Brief: Ascletis Announces First Participants Dosed In A U.S. Clinical Study Combining Adipose-Targeted, Once-Monthly Injectable Small Molecule THRβ Agonist, ASC47, And Semaglutide For The Treatment Of Obesity
20/05/2025 12:07
May 20 (Reuters) - Ascletis Pharma Inc 1672.HK: ASCLETIS ANNOUNCES FIRST PARTICIPANTS DOSED IN A U.S. CLINICAL STUDY COMBINING ADIPOSE-TARGETED, ONCE-MONTHLY INJECTABLE SMALL MOLECULE THRΒ AGONIST, ASC47, AND SEMAGLUTIDE FOR THE TREATMENT OF OBESITY ASCLETIS PHARMA INC - TOPLINE DATA FROM STUDY EXPECTED IN Q4 2025 Source text: ID:nPn60D9v5a Further company coverage: 1672.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ascletis Pharma
See all newsFactbox: Race to launch weight-loss pill heats up as Novo wins UK approval
Brief: Ascletis Announces Fixed-Dose Combination of ASC30, Once-Daily Oral Small Molecule GLP-1R Agonist, and ASC39, Once-Daily Oral Small Molecule Amylin-Selective Amylin Receptor Agonist, for Clinical Development
Factbox: Race to launch weight-loss pill heats up as Lilly wins US approval
Brief: Ascletis Pharma FY Loss Attributable Rmb359.9 Million
Brief: Ascletis Pharma Expects To Submit IND Application To U.S. FDA For ASC39 In Q3 2026